Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.

Kjetil BoyeAlessandra LonghiTormod GurenSusanne LorenzStine NæssMichela PieriniIngeborg TaksdalIngvild LobmaierMarilena CesariAnna PaioliAyca M LøndalenElisabetta SetolaIvar HomplandLeonardo A Meza-ZepedaKirsten Sundby HallEmanuela Palmerini

Published in: Cancer immunology, immunotherapy : CII (2021)

In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.

Keyphrases

open label
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
advanced non small cell lung cancer
prognostic factors
phase ii
squamous cell carcinoma
current status
single molecule
epidermal growth factor receptor
placebo controlled
double blind